- Funding to support further development of lead programme for a novel therapeutic targeting Gram-negative bacteria including Multi-Drug-Resistant strains
- Optimisation will also support application of the Alphamer® platform across other therapeutic indications, including oncology
London, UK, 25 November 2024: Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announces it has been awarded a £1M grant by PACE (Pathways to Antimicrobial Clinical Efficacy), a pioneering initiative focused on early-stage antimicrobial drug and diagnostic discovery. The funding will support the continued development of Centauri’s Alphamer® technology, in this case targeting Gram-negative bacteria including Multi-Drug Resistant (MDR) bacterial strains.
Centauri’s lead anti-infective molecules exhibit a dual mechanism of action. By binding onto the surface of the bacteria, the molecules are able to both exert their antibacterial activity and recruit naturally occurring antibodies to rapidly clear the pathogen. This novel technology is aimed to benefit the most vulnerable patients affected by life-threatening bacterial infections. The funding from PACE will also enable Centauri’s ongoing and future research across multiple therapeutic indications.
Founded in 2023, PACE is a collaboration between three leaders in the UK’s health innovation and research community - Innovate UK, LifeArc, and Medicines Discovery Catapult. The partnership aims to work with the global antimicrobial resistance (AMR) community to accelerate the speed of innovation and grow a pipeline of high-quality antimicrobial drugs and associated diagnostics.
"We are pleased that Centauri's project was selected to be funded in the first round of projects under PACE, in recognition of the value of this novel immunotherapeutic technology"commented Dr Jennifer Schneider, CEO, Centauri Therapeutics. “We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk opportunities across multiple therapeutic areas.”
Dr Beverley Isherwood, Programme Director, PACE, said: “Centauri’s immunotherapy platform provides a unique approach to addressing the rising threat of difficult-to-treat infections – one of our most complex health challenges. By working together with the brightest and best, providing support to companies such as Centauri, we aim to give leading antimicrobial innovations the greatest chance of success, advancing early-stage drug and diagnostic projects with greater speed, support, and confidence.”
